Last reviewed · How we verify

NCT07204782

Cardiovascular Disease CVD Constitutes a Significant Health Challenge for Individuals With Type 2 Diabetes Mellitus T2DM, Affecting Approximately 32% of This Population and Contributing Significantly to Global Mortality.Visceral Adipose Tissue VAT Accumulation Has Been Recognize

Not yet recruiting Last updated 2 October 2025
What this trial tests

trial in Diabete Mellitus in 238 participants. Not yet recruiting.

Timeline
1 December 2025
Primary endpoint
1 April 2027
1 July 2027

Quick facts

Lead sponsorAssiut University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment238
Start date1 December 2025
Primary completion1 April 2027
Estimated completion1 July 2027
Sites1 location across Egypt

Conditions studied

Sponsor

Assiut University

Who can join

40 and older, any sex, with Diabete Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

calculate cardiovascular risk scores in type 2 DM patients, then estimate its association with new visceral adipose tissue indices

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabete Mellitus

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07204782.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing